title: Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial.
abstract: OBJECTIVE
  ST-segment resolution (STR) after reperfusion therapy has been shown to correlate with prognosis in patients with ST-segment elevation myocardial infarction (STEMI). We investigated whether acute ECG measurements also correlate with ultimate infarct size.
  
  
  RESULTS
  The INFUSE-AMI trial randomized 452 patients with anterior STEMI to intracoronary bolus abciximab vs. no abciximab, and to thrombus aspiration vs. no aspiration. Infarct size as percentage of total LV mass was calculated by cardiac magnetic resonance imaging (MRI) 30 days post intervention. Five ECG methods were analysed for their ability to predict MRI infarct mass: (1) summed STR across all infarct-related ECG leads (ΣSTR); (2) STR in the single lead with maximum baseline ST-segment elevation (maxSTR); (3) summed residual ST-segment elevation across all infarct-related leads at 60 min post intervention (ΣST residual); (4) maximum residual ST-segment elevation in the worst single lead at 60 min post intervention (maxST residual); (5) number of new significant Q-waves (Qwave) at 60 min. All ECG methods strongly correlated with 30-day MRI infarct mass (all p<0.003). Simpler ECG measurements such as maxSTresidual and Qwave were as predictive as more complex measurements. A subset analysis of 158 patients who had microvascular obstruction (MVO) determined by MRI 5 days post intervention also showed strong correlations of MVO with the ECG measures.
  
  
  CONCLUSIONS
  ST-segment and Q-wave changes after primary PCI in anterior STEMI strongly correlated with 30-day infarct size by MRI. In particular, maxST residual and Qwave at 60 min are simple ECG parameters that offer rapid analysis for prognostication.
authors.affiliation: Columbia University, New York, NY, USA.
authors.forename: José M
authors.initials: JM
authors.lastname: Dizon
authors.forename: Sorin J
authors.initials: SJ
authors.lastname: Brener
authors.forename: Akiko
authors.initials: A
authors.lastname: Maehara
authors.forename: Bernard
authors.initials: B
authors.lastname: Witzenbichler
authors.forename: Angelo
authors.initials: A
authors.lastname: Biviano
authors.forename: Jacek
authors.initials: J
authors.lastname: Godlewski
authors.forename: Helen
authors.initials: H
authors.lastname: Parise
authors.forename: Jan-Henk
authors.initials: JH
authors.lastname: Dambrink
authors.forename: Roxana
authors.initials: R
authors.lastname: Mehran
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gibson
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
mesh_terms: D000077284:Abciximab; D056988:Anterior Wall Myocardial Infarction / Q000175:diagnosis / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D017023:Coronary Angiography; D004562:Electrocardiography; D005260:Female; D006352:Heart Ventricles / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D019028:Magnetic Resonance Imaging, Cine; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab
keywords: Cardiac magnetic resonance imaging; ST elevation myocardial infarction; ST-segment resolution; electrocardiogram